Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.53 |
| ▸ | SFRP1 | Q8N474 | 4/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4894455 | 0.89 | GPR119 (0.53) | GPR119SFRP1PIK3CATGFBR1STS | |
| SCHEMBL27703343 | 0.86 | HTR6 (0.42) | GPR119SFRP1 | |
| SCHEMBL5199608 | 0.85 | GPR119 (0.49) | GPR119 | |
| SCHEMBL4894257 | 0.84 | GPR119 (0.52) | GPR119SFRP1TGFBR1 | |
| SCHEMBL4891019 | 0.81 | SFRP1 (0.49) | GPR119SFRP1 | |
| SCHEMBL4895711 | 0.80 | GPR119 (0.48) | GPR119 | |
| SCHEMBL4898957 | 0.80 | HTR2C (0.45) | SFRP1 | |
| SCHEMBL4900251 | 0.80 | GPR119 (0.49) | GPR119STS | |
| SCHEMBL4899075 | 0.79 | GPR119 (0.51) | GPR119 | |
| Hydrochloric Acid SCHEMBL4898858 | 0.79 | HTR2C (0.44) | SFRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318933-A1 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED | 2008-12-25 | — | — | US | disclosed |
| EP-1814873-A2 | 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006038006-A2 | 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318933-A1 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | HTR6, HTR5A, TPH1 | GPR119 33/4885SFRP1 1090/4885PIK3CA 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.